Related Experiment Video
Updated: Jul 14, 2026

Preparation of N-(2-alkoxyvinyl)sulfonamides from N-tosyl-1,2,3-triazoles and Subsequent Conversion to Substituted Phthalans and Phenethylamines
Published on: January 3, 2018
Repurposing the phenylthiazole scaffold with 1,3,4-oxadiazole for selective, potent and well-tolerated antifungal
Mohamed Hagras1, Hany G Ezzat1, Abdelrahman A Abuelkhir1
1Department of Pharmaceutical Organic Chemistry, College of Pharmacy, Al-Azhar University Cairo 11884 Egypt m.hagrs@azhar.edu.eg.
Abstract:
Invasive fungal infections (IFIs) represent a critical health threat, particularly among immunocompromised individuals, with mortality rates reaching up to 50%. The growing resistance to existing antifungal therapies necessitates the development of novel agents. Here, we rationally designed phenylthiazole-based oxadiazole derivatives to enhance selectivity and potency against resistant fungal strains. Among the tested compounds, compound 35 (which emerged as a lead candidate) demonstrated potent activity against Candida albicans (MIC = 1-2 μg mL-1), Candida glabrata (MIC = 0.5-1 μg mL-1), and multidrug-resistant Candida auris (MIC = 2-4 μg mL-1), outperforming fluconazole and matching amphotericin B. Additionally, compound 35 showed minimal cytotoxicity (88% cell viability at 16 μg mL-1) and negligible hemolytic activity, indicating a superior safety profile.
Insights
Novel phenylthiazole-based oxadiazole derivatives show potent antifungal activity against resistant strains like Candida auris. Compound 35 is a promising lead candidate with a favorable safety profile, addressing the urgent need for new antifungal therapies.
Area of Science:
- Medicinal Chemistry
- Mycology
- Infectious Diseases
Background:
- Invasive fungal infections (IFIs) pose a significant threat, especially to immunocompromised patients, with high mortality rates.
- Increasing antifungal resistance necessitates the development of novel therapeutic agents.
- Existing treatments face challenges due to resistance and toxicity.
Purpose of the Study:
- To rationally design and synthesize novel phenylthiazole-based oxadiazole derivatives.
- To evaluate the antifungal activity and selectivity of these derivatives against resistant fungal strains.
- To identify a lead compound with enhanced potency and an improved safety profile.
Main Methods:
- Rational drug design and synthesis of phenylthiazole-based oxadiazole derivatives.
- Antifungal susceptibility testing using Minimum Inhibitory Concentration (MIC) assays.
- Cytotoxicity and hemolytic activity assays to assess safety profile.
Main Results:
- Compound 35 demonstrated potent activity against *Candida albicans*, *Candida glabrata*, and multidrug-resistant *Candida auris*.
- MIC values for compound 35 ranged from 0.5-4 μg mL⁻¹, outperforming fluconazole.
- Compound 35 exhibited minimal cytotoxicity and negligible hemolytic activity, suggesting a favorable safety profile.
Conclusions:
- Phenylthiazole-based oxadiazole derivatives represent a promising class of novel antifungal agents.
- Compound 35 is a potential lead candidate for developing new treatments against invasive fungal infections, including those caused by resistant strains.
- The favorable safety profile of compound 35 warrants further investigation for clinical development.
Related Concept Videos
Preparation of 1° Amines: Hofmann and Curtius Rearrangement Overview
Aryldiazonium Salts to Azo Dyes: Diazo Coupling
Antifungal Agents
Antiprotozoal Agents
![Cercosporin-Photocatalyzed [4+1]- and [4+2]-Annulations of Azoalkenes Under Mild Conditions](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F60786.jpg&w=3840&q=50)
